Otitis Clinical Trials

Find Otitis Clinical Trials Near You

Observatory of Streptococcus Pneumoniae Nasopharyngeal Carriage in Infants With Acute Otitis Media (AOM) and in Healthy Children

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This nasopharyngeal (NP) carriage surveillance study was requested by the European Agency for the Evaluation of Medicinal Products as a post-licensing commitment to determine whether the use of the pneumococcal conjugate vaccines (PCVs) including 7 then 13 valents (introduced in 2001 and 2010, respectively) caused a shift in the distribution of Streptococcus pneumoniae serotypes in children with acute otitis media and modified the resistance of this bacterial species to antibiotics.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 6 months
Maximum Age: 15
Healthy Volunteers: t
View:

• both sexes

• suffering from suppurative AOM or healthy children

‣ age: 6 months to 36 months for AOM

⁃ age: 6 months to 15 years for healthy children

• informed consent from parents or guardians

• Children who haven't received antibiotic treatment within 7 days before enrollment,

Locations
Other Locations
France
ACTIV
RECRUITING
Créteil
Contact Information
Primary
Corinne Levy, MD
corinne.levy@activ-france.fr
0033148850404
Backup
Stéphane Béchet, MsC
stephane.bechet@activ-france.fr
0033148850404
Time Frame
Start Date: 2001-09-11
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 25760
Treatments
Other: prospective cohort: Main study
700 children aged 6 to 36 months with AOM and 500 healthy control children aged 6 months to 15 years will be enrolled. A mandatory nasopharyngeal swab is planned for these groups.
Other: ESBL cohort- Ancillary study
For a subgroup of approximately 500 children with AOM, aged 6 to 24 months, optional stool or anorectal swab samples will be collected.
Other: Optional Nasopharyngeal sample
For a subgroup of 560 children with AOM, an optional nasal sample will be collected to assess the association of various respiratory viruses (SARS-CoV-2, RSV, Influenza A, Influenza B) with different pneumococcal serotypes.
Related Therapeutic Areas
Sponsors
Leads: Association Clinique Thérapeutique Infantile du val de Marne
Collaborators: Pfizer

This content was sourced from clinicaltrials.gov